Spineart SA
$5.1M 233 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Nevro Corp.
Nevro Corp. reported $5,017,526.27 across General Payments, Research, and Ownership to 30,803 physicians and teaching hospitals across 31,030 transactions.
- $5.0M Top quartile payer
- All-tracks total
- 31,030 Top 10% volume
- Transactions
- 30,803 Top 10% reach
- Recipients
- −$94.9K
- General Payments vs PY2023
Nevro Corp. reported $5,017,526.27 across all CMS Open Payments tracks (General + Research + Ownership) to 30,803 physicians and teaching hospitals in Program Year 2024 - ranking #277 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,492,462.50, averaging $162.89 per recipient.
How Nevro Corp.'s $5.0M all-tracks total breaks down
Nevro Corp.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
87/100
Total payments
D
56/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nevro-corp Nevro Corp.
$5.0M · #277/1,925 · 0.0% industry · PY2024
- TOT $5.0M
- RANK #277
- SHARE 0.0%
- TXN 31,030
- RCP 30,803
- CAT 7
- GEN $2.5M
- ΔGEN −$94.9K
- TOP1 5.5%
- PY 2024
Volume peers
Nearest volume peer: Spineart SA ($5.1M)
Nevro Corp. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Nevro Corp.'s CMS-reported General Payments decreased by $94.9K (−3.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NEVRO CORP.PY2023: NEVRO CORP.PY2024: Nevro Corp.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,587,358.51
- PY2024
- $2,492,462.50
What the Data Shows for Nevro Corp.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Nevro Corp., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
28,540 transactions worth $1.1M make "Food and Beverage" the top general-payment category in the 7-category breakdown below, 45.6% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Nevro Corp.'s 7-category general-payment breakdown at $1.1M, 45.6% of the reported total.
Nevro Corp. reports 7 general-payment categories - the top three are Food and Beverage (45.6%), Consulting Fee (21.2%), and Compensation for Faculty or Speaker (Medical Education) (19.5%). The remaining 4 categories make up 13.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Nevro Corp. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.1M | 28,540 | 45.6% |
| Consulting Fee | $527.8K | 338 | 21.2% |
| Compensation for Faculty or Speaker (Medical Education) | $486.7K | 231 | 19.5% |
| Compensation for Services Other Than Consulting | $174.4K | 69 | 7.0% |
| Travel and Lodging | $149.3K | 1,590 | 6.0% |
| Grant | $11.8K | 2 | 0.5% |
| Education | $4.7K | 33 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $469,113.05 (18.8%) of $2,492,462.50 in this company's General Payments records across 10,588 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Nevro Corp.
The five named recipients with the highest reported General Payments from this company
- 1
Usman Latif
$136,218.38 across 167 reported transactions
- 2
Alexander Escobar
$99,716.22 across 115 reported transactions
- 3
Brett Himmelwright
$92,681.46 across 46 reported transactions
- 4
Jason Dunleavy
$75,639.39 across 96 reported transactions
- 5
Douglas Beall
$64,857.60 across 82 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Nevro Corp. ranks #277 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,683 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Dompe US, Inc. : $1.3M total payments, HHI 111
- ADC Therapeutics America, Inc. : $1.1M total payments, HHI 111
- Kyowa Kirin, Inc. : $2.5M total payments, HHI 111
- Xeris Pharmaceuticals, Inc. : $1.2M total payments, HHI 110
- Mallinckrodt Hospital Products Inc. : $7.6M total payments, HHI 109
- Lexicon Pharmaceuticals, Inc. : $2.5M total payments, HHI 108
- Nevro Corp. (this company) : $2.5M total payments, HHI 107
- Almatica Pharma LLC : $421.9K total payments, HHI 106
- Vifor Pharma, Inc. : $368.6K total payments, HHI 106
- Grifols USA, LLC : $2.0M total payments, HHI 105
- Neurelis, Inc. : $1.9M total payments, HHI 104
- ACADIA Pharmaceuticals Inc : $2.6M total payments, HHI 102
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Nevro Corp.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nevro Corp..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Nevro Corp..
Showing 6 of 1,924 companies with CMS-reported payment data.
American Medical Technology Inc
$5.1M 0 recipients
Compare payment profiles
Jcbd, LLC
$5.1M 10 recipients
Compare payment profiles
Corium, LLC
$4.9M 76,330 recipients
Compare payment profiles
ADC Therapeutics America, Inc.
$5.1M 4,269 recipients
Compare payment profiles
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
Put this to use
Nevro Corp. ranks #277 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Nevro Corp. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Nevro Corp.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.